Mahsa Nikkhoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahsa Nikkhoo has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Jayant Kirtane
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York, USA
1 shared publication Ali Bozorgi
Tehran Heart Center
1 shared publication- Armin Elahifar
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Institute , Tehran 1995614331
1 shared publication - Azita Hajhossein Talasaz
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Bahram Mohebbi
Iran University of Medical Sciences
1 shared publication - Behnood Bikdeli
Heart and Vascular Institute, Brigham and Women’s Hospital , Mass General Brigham, Boston, MA
1 shared publication
Latest Publications
- Open Access
- 26 September 2026
- Published by Maad Rayan Publishing Company in Journal of lasers in medical sciences
- Vol. 17, e52056
Effectiveness of Low-Level and High-level Laser Therapy for Rotator Cuff–Related Shoulder Disorders: A Systematic Review and Meta-Analysis
Introduction: While photobiomodulation and high-power lasers are common for rotator cuff-related shoulder pain, evidence interpretation is hindered by inconsistent dosimetry and clinical findings. This systematic review and meta-analysis evaluate the effects of low-level (LLLT) and high-level laser therapy (HLLT) on pain, range of motion (ROM), and shoulder function. Methods: This PROSPERO-registered review included randomized controlled trials comparing LLLT or HLLT against sham, no treatment, or conventional care. Two reviewers independently conducted screening, data extraction, and risk-of-bias assessment. Continuous outcomes were synthesized using random-effects models, supplemented by subgroup analyses (LLLT vs. HLLT; laser vs. laser plus exercise) and sensitivity analyses to address heterogeneity. Results: Twenty-three trials (wavelengths 805–1064 nm) were included. Pooled analysis showed that laser therapy significantly reduced overall pain (VAS: MD −5.22; 95% CI −7.56 to −2.88; P<0.001 P<0.001 P<0.001), though improvements in pain at rest, during movement, and at night were not statistically significant. After excluding outliers, modest improvements were noted in active internal rotation (MD 1.14; 95% CI 0.19–2.09; P<0.001 P<0.001 P<0.001) and passive external rotation (MD −1.33; 95% CI −1.92 to −0.73; P<0.001 P<0.001 P<0.001). Subgroup analysis indicated that HLLT yielded superior active-abduction outcomes compared to LLLT (P=0.016 P=0.016 P=0.016). Certainty was limited by heterogeneity, small sample sizes, inconsistent dosimetry, and short follow-up. Conclusion: Laser therapy provides modest, reproducible analgesic benefits, and selective ROM improvements, particularly when HLLT is combined with exercise. Given the limited functional gains and reporting inconsistencies, lasers should be used as an adjunct to structured rehabilitation rather than a standalone treatment. Future trials require standardized dosing and longer follow-ups.
- 26 September 2026
- Published by Maad Rayan Publishing Company in Journal of lasers in medical sciences
- Vol. 17, e52056
Open AccessEffectiveness of Low-Level and High-level Laser Therapy for Rotator Cuff–Related Shoulder Disorders: A Systematic Review and Meta-Analysis
Introduction: While photobiomodulation and high-power lasers are common for rotator cuff-related shoulder pain, evidence interpretation is hindered by inconsistent dosimetry and clinical findings. This systematic review and meta-analysis evaluate the effects of low-level (LLLT) and high-level laser therapy (HLLT) on pain, range of motion (ROM), and shoulder function. Methods: This PROSPERO-registered review included randomized controlled trials comparing LLLT or HLLT against sham, no treatment, or conventional care. Two reviewers independently conducted screening, data extraction, and risk-of-bias assessment. Continuous outcomes were synthesized using random-effects models, supplemented by subgroup analyses (LLLT vs. HLLT; laser vs. laser plus exercise) and sensitivity analyses to address heterogeneity. Results: Twenty-three trials (wavelengths 805–1064 nm) were included. Pooled analysis showed that laser therapy significantly reduced overall pain (VAS: MD −5.22; 95% CI −7.56 to −2.88; P<0.001 P<0.001 P<0.001), though improvements in pain at rest, during movement, and at night were not statistically significant. After excluding outliers, modest improvements were noted in active internal rotation (MD 1.14; 95% CI 0.19–2.09; P<0.001 P<0.001 P<0.001) and passive external rotation (MD −1.33; 95% CI −1.92 to −0.73; P<0.001 P<0.001 P<0.001). Subgroup analysis indicated that HLLT yielded superior active-abduction outcomes compared to LLLT (P=0.016 P=0.016 P=0.016). Certainty was limited by heterogeneity, small sample sizes, inconsistent dosimetry, and short follow-up. Conclusion: Laser therapy provides modest, reproducible analgesic benefits, and selective ROM improvements, particularly when HLLT is combined with exercise. Given the limited functional gains and reporting inconsistencies, lasers should be used as an adjunct to structured rehabilitation rather than a standalone treatment. Future trials require standardized dosing and longer follow-ups.
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Open AccessCoated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- Open Access
- 11 May 2024
- Published by Wiley
Syncope secondary to recurrent episodes of torsade de pointes following androgen-deprivation therapy: a case report
Syncope secondary to recurrent episodes of torsade de pointes following androgen-deprivation therapy: a case report
- 11 May 2024
- Published by Wiley
Open AccessSyncope secondary to recurrent episodes of torsade de pointes following androgen-deprivation therapy: a case report
Syncope secondary to recurrent episodes of torsade de pointes following androgen-deprivation therapy: a case report